Key Market Indicators
Sales of Estonian antirheumatic medicine are projected to reach $14 million by 2026, growing 1.7% each year on average since 2004. The country currently ranks 21st in this sector, with Ireland ahead at $13 million. Germany, Spain and Canada follow at 2nd, 3rd and 4th respectively.
